Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on ABSI. Absci Corporation’s share was trading at $7.27 as of June 15th.
Pressmaster/Shutterstock.com
Absci Corporation (ABSI) is a clinical-stage biopharmaceutical company focused on transforming drug discovery through the use of generative artificial intelligence, positioning itself at the forefront of a rapidly growing trend toward AI-enabled drug development. The company’s lead program, ABS-201, is an antibody-based therapy designed to treat androgenetic alopecia, or pattern hair loss, by targeting a protein pathway involved in hair follicle biology.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
ABS-201 represents a significant milestone for the company, as it has advanced from an AI-designed concept into human clinical testing, demonstrating the practical application of Absci’s technology platform and validating its ability to accelerate the drug development process. Investor enthusiasm is increasingly centered on the ongoing HEADLINE clinical trial, where encouraging early safety data has supported confidence in the program’s potential and highlighted the company’s ability to move candidates into the clinic faster and at a lower cost than traditional biotechnology approaches.
Beyond hair loss, Absci’s broader platform offers opportunities across multiple therapeutic areas, including endometriosis, expanding the commercial potential of its pipeline and creating additional avenues for long-term value creation. The company is also benefiting from a broader industry shift as pharmaceutical companies and investors place greater emphasis on platforms capable of shortening development timelines and improving research productivity.
This growing recognition of AI-driven drug discovery has strengthened the investment case for Absci, particularly as it continues to generate clinical evidence supporting its technology. With ABS-201 progressing through human trials, a differentiated platform, and exposure to large underserved markets, Absci is positioned to benefit from both advancing clinical milestones and increasing adoption of AI-powered drug development, creating meaningful upside potential if its programs continue to demonstrate favorable results.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, improving reimbursement adoption, and significant upside from its gene-editing pipeline. CRSP’s stock price has appreciated by approximately 28.41% since our coverage. TradersPro shares a similar view but emphasizes on AI-driven drug discovery, with Absci Corporation’s thesis centered on accelerating antibody development and advancing AI-designed therapies into human clinical trials.
Absci Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 23 hedge fund portfolios held ABSI at the end of the first quarter which was 16 in the previous quarter. While we acknowledge the risk and potential of ABSI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABSI and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
